OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center

home / authors / adam-m-brufsky-md-phd-university-of-pittsburgh-upmc-hillman-cancer-center

Articles

Advertisement

Adam M. Brufsky, MD, PhD, FACP

Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

January 5th 2022

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Read More


Using Oral Therapies to Advance Care in MBC

Using Oral Therapies to Advance Care in MBC

February 16th 2021

Read More


Oral Therapies and Dose Reductions in MBC

Oral Therapies and Dose Reductions in MBC

February 16th 2021

Read More


MBC Therapy: Tesetaxel/Capecitabine

MBC Therapy: Tesetaxel/Capecitabine

February 16th 2021

Read More


Metastatic Breast Cancer Therapy: OPE

Metastatic Breast Cancer Therapy: OPE

February 9th 2021

Read More


At-Home Administration of Therapies to Treat MBC

At-Home Administration of Therapies to Treat MBC

February 9th 2021

Read More

Advertisement

Advantages of Oral Therapy for Metastatic Breast Cancer

Advantages of Oral Therapy for Metastatic Breast Cancer

February 2nd 2021

Read More


Chemotherapy to Treat MBC: Drug Developments

Chemotherapy to Treat MBC: Drug Developments

February 2nd 2021

Read More


Predicting Response to Chemotherapy in Metastatic Breast Cancer

Predicting Response to Chemotherapy in Metastatic Breast Cancer

January 26th 2021

Read More


Metastatic Breast Cancer: Chemotherapy Selection

Metastatic Breast Cancer: Chemotherapy Selection

January 26th 2021

Read More


Assessing Response to Chemotherapy in Metastatic Breast Cancer

Assessing Response to Chemotherapy in Metastatic Breast Cancer

January 19th 2021

Read More


Cytotoxic Chemotherapy for Metastatic Breast Cancer

Cytotoxic Chemotherapy for Metastatic Breast Cancer

January 19th 2021

Read More

Advertisement

Long-Term Disease Control in Metastatic Breast Cancer

Long-Term Disease Control in Metastatic Breast Cancer

January 19th 2021

Read More


Treatment Advances in Metastatic Breast Cancer

Treatment Advances in Metastatic Breast Cancer

January 19th 2021

Read More

Latest Conference Coverage

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact